Accumulate Caplin Point Laboratories; target of Rs 1675: Asit C Mehta

Asit C Mehta report on Caplin Point Laboratories

Caplin Point Laboratories Limited (CAPLIPOINT) is an India-based pharmaceutical company. The company is engaged in the production, development, and marketing of a range of generic formulations and branded products, exporting them to overseas markets. Its products include tablets, dry syrups (bottles), soft gels, capsules, suppositories, liquid syrups (bottles), liquid injectables in ampoules and vials, lyophilized vials, prefilled syringes (PFS), emulsion injections in ampoules and vials, ophthalmic droppers, pre-mix bags, topicals, and sachets (liquids and powders). It also manufactures a range of ointments, creams, gels, and lotions. Its manufacturing facilites are located in Puducherry & Tamil Nadu in India. It has a presence in LATAM (Latin America), Southern Africa, and Francophone Africa, along with a presence in the United States of America and the European region. The company’s subsidiaries include Caplin Point Far East Limited and Caplin Steriles Limited.

Outlook

Therefore, we recommend Caplin Point Laboratories Limited with a target price of Rs 1,675, based on FY26E EPS of Rs 83.7 and a forward PE valuation multiple of 20. It appears to be a value buy with growth potential at current levels. As a result, we recommend an ACCUMULATE rating for the long term.